Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. (Q40616342)
Jump to navigation
Jump to search
scientific article published on November 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. |
scientific article published on November 2003 |
Statements
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis (English)
Ali R Jazirehi
Xiao-Hu Gan
Sven De Vos
Christos Emmanouilides
Benjamin Bonavida
1 November 2003